In a Nutshell
The peptide marketed most specifically for sleep is DSIP (delta sleep-inducing peptide). In July 2026, FDA's advisory committee reviewed seven peptides and recommended six of them for compounding eligibility. DSIP was the one it declined — voted down 6–7, with members citing insufficient evidence and the availability of approved alternatives 1.
The Pharmacy Compounding Advisory Committee (PCAC) voted 6 yes / 7 no / 1 abstention against recommending the emideltide substances for the 503A Bulks List. That is meaningful regulatory context — but it is not a finding that DSIP is unsafe or ineffective, and FDA has not made a final decision. The stronger reason for caution is the underlying record: small, inconsistent, intravenous studies, no validated subcutaneous regimen, and no clinical safety dataset for the proposed route.
There is a real relationship between peptides and sleep, but it runs the other way round from how it is usually sold. Your largest natural growth hormone pulse occurs during deep sleep. Sermorelin directly activates pituitary GHRH receptors to stimulate growth hormone release — it does not merely amplify a signal your sleep creates. Evening dosing is chosen to align administration with normal nocturnal physiology. Some patients describe changes in sleep during treatment, but that is anecdotal and does not establish a predictable effect, and sermorelin is not an approved insomnia treatment.
Which points at the honest conclusion: for poor sleep specifically, the interventions with real evidence are not peptides, and several of the underlying causes are things a clinic can actually find and treat.
DSIP: Why the Panel Said No
DSIP was isolated in the 1970s from rabbits during induced sleep, and named for the delta-wave activity it appeared to promote. It has been studied intermittently ever since.
Despite roughly fifty years of study, its physiological role remains poorly defined and reported effects across studies have been inconsistent. FDA staff stated there is a lack of safety and efficacy data supporting its use; committee members voting against cited insufficient evidence and available approved alternatives 1.
FDA's separate published position is that compounded emideltide "may pose risk for immunogenicity for certain routes of administration," with no safety-related information identified for the proposed route 2.
Full detail: DSIP (emideltide).
What About Other Peptides?
Sermorelin and growth hormone secretagogues — the relationship is real but indirect. These are dosed at night to align with the natural growth-hormone pulse during slow-wave sleep, and some patients describe changes in sleep during treatment. That is anecdotal and uncontrolled; it does not establish a predictable treatment effect, and controlled evidence for sleep outcomes in adults is limited.
BPC-157 — a common search is whether it improves sleep. There is no controlled human evidence that it does. See BPC-157.
Epitalon — derived from pineal gland research, and the indication FDA's committee considered was insomnia. It received a favorable advisory vote, but that reflects a judgment about compounding eligibility rather than demonstrated efficacy, and controlled human sleep-outcome data is absent. See Epitalon.
Selank — marketed for stress and sleep. No controlled human evidence for sleep outcomes.
The Question to Answer First: Is It Sleep Apnea?
Before considering anything for sleep, this needs excluding — because it is common, badly underdiagnosed, and makes every other intervention fail.
Signs worth acting on:
- Loud snoring, particularly with witnessed pauses in breathing
- Waking gasping or choking
- Waking unrefreshed despite adequate time in bed
- Significant daytime sleepiness
- Morning headaches
- Nocturia — waking repeatedly to urinate
Untreated sleep apnea is associated with cardiovascular risk, metabolic dysfunction and daytime impairment. Sedating substances can make it worse. If any of the above applies, get assessed before adding anything.
What Actually Works for Sleep
The evidence-based options are genuinely good, and this is where the gap between what is marketed and what works is widest.
CBT-I (cognitive behavioral therapy for insomnia) is first-line, with the strongest evidence base of any insomnia treatment — and unlike medication, its benefits persist after treatment ends.
Treat the underlying driver. Thyroid dysfunction, iron deficiency, depression and anxiety, alcohol, medication timing, and chronic pain all disrupt sleep and are all addressable.
Hormonal change is frequently the cause in midlife, and this is where peptide marketing most often diverts people from something that works. Perimenopausal and menopausal sleep disruption — including night sweats and the characteristic 3 a.m. waking — responds to treating the hormonal change directly far better than to sedation layered on top. See menopause insomnia, waking at 3 a.m. and night sweats.
Sleep hygiene fundamentals — consistent timing, light exposure, a cool dark room, limiting alcohol and late caffeine. Modest alone, but they make everything else work better.
Red Flags — Seek Care
- Witnessed breathing pauses, gasping or choking during sleep — get assessed for sleep apnea
- Falling asleep unintentionally during the day, particularly while driving — urgent
- Sudden severe insomnia with mood change, or thoughts of self-harm — seek help immediately; call or text 988 in the US
- Excessive sedation or difficulty waking, especially when combining sedating substances
- Fever, spreading redness or swelling at an injection site
Get Started with JumpstartMD
If poor sleep is what brought you here, the most useful thing we can tell you is that an unapproved peptide — including the one an FDA panel has just declined — is unlikely to be your best option, and the alternatives are better than most people realize.
JumpstartMD was founded in 2007 by Stanford-trained physicians, with programs built around labs, hormones and body composition. You are seen face-to-face by licensed clinicians — in person at 14 California locations or online across California — beginning with 60-biomarker lab screening and InBody® body composition scanning. InBody scans are done in clinic; online members can book one at any of the 14 locations.
Sleep disruption in midlife is frequently hormonally driven, and it is one of the areas where identifying the cause changes the outcome most. Thyroid function, iron status and hormonal change are all measurable, and treating what the labs show is the better-evidenced route than sedation.
Sermorelin is supplied as a compounded preparation, not an FDA-approved finished drug: GEREF was historically approved for diagnostic use and pediatric growth hormone deficiency — not adult sleep, recovery, body-composition or healthy-aging goals — and controlled evidence for those adult outcomes remains limited.
Peptide care is offered through a paid membership, subject to clinical evaluation. Contact JumpstartMD for membership details and pricing.
Clinician-guided peptide therapy may be considered after an individualized clinical evaluation. Certain therapies may use compounded medications, which are not FDA-approved, and evidence, risks and expected outcomes vary by treatment. See peptide therapy.
Book FREE Consultation
Share your details and a JumpstartMD team member will reach out shortly. Or call 408.478.3496 for your free, no-obligation consultation.
Share your details and a JumpstartMD team member will reach out when we open.
Related Articles
- DSIP (Emideltide) — the peptide the FDA panel declined
- Menopause Insomnia — hormonally driven sleep disruption
- Waking at 3 a.m.
- Sermorelin Dosing and Administration — the rationale for evening administration
- The Downsides of Peptide Therapy
Frequently Asked Questions
Which peptides make you sleepy?
DSIP is the one marketed most specifically for sleep, though an FDA advisory committee declined to recommend it in July 2026, citing insufficient evidence. Growth hormone secretagogues such as sermorelin are dosed in the evening and drowsiness is among the reported effects, but they are not sedatives and are not sleep treatments.
Does BPC-157 improve sleep?
There is no controlled human evidence that BPC-157 improves sleep. It is marketed primarily for tissue repair, and its human evidence base is one abstract-only 2005 trial of an enema formulation for colitis.
Do peptides actually help you sleep?
For most peptides marketed for sleep there is no controlled human trial evidence. The evidence for DSIP is weak rather than simply absent: small controlled studies produced inconsistent findings, and none establishes the marketed subcutaneous use. CBT-I and treating underlying causes have far stronger evidence.
Why is sermorelin taken at night?
Your largest natural growth hormone pulse occurs during deep sleep, so evening dosing means the stimulus arrives when your pituitary is primed to respond. Evidence that poor sleep reduces sermorelin's pharmacological effect is limited: sermorelin acts directly on pituitary GHRH receptors, and evening dosing aligns it with normal nocturnal physiology.
What is the best treatment for insomnia?
CBT-I has the strongest evidence base and its benefits persist after treatment ends. Alongside it, identifying and treating the driver matters — sleep apnea, thyroid dysfunction, iron deficiency, depression, alcohol, medication timing, and in midlife, hormonal change.
Can menopause cause insomnia?
Yes, commonly — through night sweats, hormonal effects on sleep architecture, and the characteristic pattern of waking in the early hours. It frequently responds better to treating the hormonal change directly than to sedatives. See menopause insomnia.
References
- Regulatory Affairs Professionals Society, "FDA advisory committee backs two more peptides, rejects one for compounding list," Jul. 2026. [Online]. Available: https://www.raps.org/resource/fda-advisory-committee-backs-two-more-peptides-rejects-one-for-compounding-list.html [Accessed: Jul. 25, 2026]. ↩
- U.S. Food and Drug Administration, "Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks." [Online]. Available: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks [Accessed: Jul. 25, 2026]. ↩
- D. Riemann, C. A. Espie, E. Altena, E. S. Arnardottir, C. Baglioni, C. L. A. Bassetti, C. Bastien, N. Berzina, B. Bjorvatn, D. Dikeos, et al., "The European Insomnia Guideline: An update on the diagnosis and treatment of insomnia 2023," Journal of Sleep Research, vol. 32, no. 6, p. e14035, Dec. 2023, [Online]. Available: https://doi.org/10.1111/jsr.14035. PMID: 38016484. [Accessed: Jul. 25, 2026]. ↩
- E. Van Cauter, L. Plat, "Physiology of growth hormone secretion during sleep," The Journal of Pediatrics, vol. 128, no. 5 Pt 2, pp. S32-7, May 1996, [Online]. Available: https://doi.org/10.1016/s0022-3476(96)70008-2. PMID: 8627466. [Accessed: Jul. 25, 2026]. ↩
- I. Sönmez, A. Vo Dupuy, K. S. Yu, J. Cronin, J. Yee, A. Azarbarzin, "Unmasking obstructive sleep apnea: Estimated prevalence and impact in the United States," Respiratory Medicine, vol. 248, p. 108348, Nov. 2025, [Online]. Available: https://doi.org/10.1016/j.rmed.2025.108348. PMID: 40957495. [Accessed: Jul. 25, 2026]. ↩